Higher Phosphorus, Cardiovascular Disease (CVD) Not Linked in Kidney Disease (CKD) Patients
Each 0.5 mg/dL increment in serum phosphorus associated with 58% increased odds of CHF.
PHILADELPHIA—Higher serum phosphorus levels are not associated with an increased risk of cardiovascular disease (CVD) among individuals with chronic kidney disease, according to study findings presented at Kidney Week 2014.
Using data from the Kaiser Permanente Southern California database, Dean Kujubu, MD, and colleagues at the Department of Nephrology & Hypertension at Kaiser Permanente Los Angeles Medical Center conducted a cross-sectional study of 195,097 patients across various estimated glomerular filtration rate (eGFR ranges (90 or higher, 60-89, 30-59, and less than 30 mL/min/1.73 m2) from January 1999 to December 2009.
The study excluded patients who were on dialysis or who had kidney transplants. The primary outcome was a composite of coronary artery disease (CAD), congestive heart failure (CHF), and cerebrovascular accident (CVA).
Overall, each 0.5 mg/dL increment in serum phosphorus was not associated with the primary outcome, but it was associated with a 58% increased odds of CHF.
Among patients with an eGFR of greater than 89 mL/min/1.73 m2, each 0.5 mg/dL increase in serum phosphorus was associated with 23% increased odds for the composite endpoint.
“In a large, diverse population, we did not observe increased risk of prevalent CAD, CHF, and CVA with higher serum phosphorus levels among individuals with eGFR of less than 89 ml/min,” the authors concluded.